Summary
A small liraglutide trial found a difference in abdominal fat without a statistically clear difference in overall weight loss. The scale was only part of the picture.
What researchers compared
Researchers in Beijing randomized 96 adults with obesity and type 2 diabetes to liraglutide or a diet-and-exercise program for 12 weeks, alongside their existing diabetes medicines. Results covered 47 medication participants and 38 lifestyle participants who completed follow-up.
cm²; completer analysis of 96 randomized adults
Original visual based on the study.
| Group or measure | Result |
|---|---|
| Liraglutide | −7.1 cm² |
| Lifestyle | +0.91 cm² |
What changed
CT-measured visceral fat—the fat around abdominal organs—fell by an average 7.1 cm² with liraglutide, versus a 0.91 cm² increase with lifestyle treatment. This measures an area, not kilograms of fat.
Average weight loss was 3.06 kg versus 1.83 kg. That difference was not statistically clear, nor was the difference in total fat-mass loss.
What to keep in perspective
Ten lifestyle participants dropped out versus one liraglutide participant, making the comparison less secure. Nausea affected 16 of 47 medication completers; one participant stopped because injections were intolerable.
This short study cannot establish long-term health benefits or muscle preservation. National hospital research funding supported it.